PDS Biotech Clinical Update and Financial Results by Mark Eisenberg 27.03.2024 Published results show a 36-month survival rate of 20% with immunotherapy. ICI resistant group had a 72% 12-month OS rate. ...
Coya Therapeutics Secures Key Therapy License by Lilu Anderson 13.02.2024 Clinical-stage biotech company Coya Therapeutics expands its IP portfolio with a license for a novel combination therapy using low dose ...